EDISON EQUITY RESEARCH - THRESHOLD PHARMACEUTICALS
September 24 2014 - 1:11PM
InvestorsHub NewsWire
EDISON EQUITY
RESEARCH: THRESHOLD PHARMACEUTICALS - PIVOTAL STS PHASE
III CONTINUES AS PLANNED
The conclusion of the interim efficacy and safety analysis of
Threshold’s ongoing Phase III soft tissue sarcoma (STS) trial is
for the study to continue as planned, in line with both our and
management’s expectations. Based on the current event rate, the
number of events (n=434 deaths) required for the primary efficacy
analysis are expected to be reached in H215. STS could be the first
approved indication for TH-302.
Threshold Pharmaceuticals is a US oncology company focused on
tumour hypoxia, a low-oxygen condition found in most solid tumours
and some blood cancers. TH-302 is in Phase III for STS and
pancreatic cancer, in addition to trials in multiple other cancers
and is partnered with Merck KGaA.
To view our full report, please click here:
http://www.edisoninvestmentresearch.com/research/report/threshold-pharmaceuticals8
Click here to view all of Edison Investment
Research’s published reports
Molecular Templates (NASDAQ:MTEM)
Historical Stock Chart
From Apr 2024 to May 2024
Molecular Templates (NASDAQ:MTEM)
Historical Stock Chart
From May 2023 to May 2024